In vitro amoebicidal activity of Salvia staminea and Salvia caespitosa on Acanthamoeba castellanii and their cytotoxic potentials on corneal cells

Journal of Ocular Pharmacology and Therapeutics

Volumn 25, Issue 4, 2009, Pages 293-298

  Goze, Ismihan ^a   Alim, Ahmet ^b   Dag, Seker ^a   Tepe, Bektas ^a   Polat, Zubeyde Akin ^a  

^a CUMHURIYET UNIVERSITY   (Turkey)

^b Public Health Laboratory   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIAMEBIC AGENT; PLANT EXTRACT; SALVIA CAESPITOSA EXTRACT; SALVIA STAMINEA EXTRACT; UNCLASSIFIED DRUG;

ACANTHAMOEBA CASTELLANII; AGAR DIFFUSION; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORNEA CELL; CYTOTOXICITY; DRUG ACTIVITY; DRUG EFFICACY; IN VITRO STUDY; NONHUMAN; RABBIT; SALVIA; SALVIA CAESPITOSA; SALVIA STAMINEA; TROPHOZOITE;

ACANTHAMOEBA CASTELLANII; ACANTHAMOEBA KERATITIS; AMEBICIDES; ANIMALS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIUM, CORNEAL; MICROSCOPY; PLANT EXTRACTS; RABBITS; SALVIA; TROPHOZOITES;

EID: 68549130628     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2008.0132     Document Type: Article

References (48)

1. Visvesvara, G.S. Free-living pathogenic amoebae. In: Lennette, E.H., Hausler, W.J., Truant, J.P., eds., Manual of Clinical Microbiology, 3rd edn. Washington, DC: Am Soc Microbiol, 1980:704-708.
2. Martinez, A.J., and Visvesvara, G.S. Free-living, amphizoic and opportunistic amebas. Brain Pathol. 7:583-598, 1997.
3. Hay, J., and Seal, D.V. Acanthamoeba keratitis: risk factors and outcome. Br. J. Ophthalmol. 80:773-774, 1996. (Pubitemid 26334929)
4. Marciano-Cabral, F., Puffenbarger, R., and Cabral, G.A. The increasing importance of Acanthamoeba infections. J. Eukaryot. Microbiol. 47:29-36, 2000.
5. Driebe, W.T. Present status of contact lens-induced corneal infections. Ophthalmol. Clin. North Am. 16:485-494, 2003. (Pubitemid 37193809)
6. Khan, N.A. Pathogenesis of Acanthamoeba infections. Microb. Pathol. 34:277-285, 2003.
7. Seal, D.V. Acanthamoeba keratitis update-incidence, molecular epidemiology and new drugs for treatment. Eye 17:893-905, 2003. (Pubitemid 37541042)
8. Feingold, J.M., Abraham, J., Bilgrami, S., et al. Acanthamoeba meningoencephalitis following autologous peripheral stem cell transplantation. Bone Marrow Transplant. 22:297-300, 1998. (Pubitemid 28382998)
9. Rosenberg, A.S., and Morgan, M.B. Disseminated acanthamoebiasis presenting as lobular panniculitis with necrotizing vasculitis in a patient with AIDS. J. Cutan. Pathol. 28:307-313, 2001.
10. Marciano-Cabral, F., and Cabral, G.A. Acanthamoeba spp. as agents of disease in humans. Clin. Microbiol. Rev. 16:273-307, 2003. (Pubitemid 36519813)
11. Carter, W.W., Gompf, S.G., Toney, J.F., et al. Disseminated Acanthamoeba sinusitis in a patient with AIDS: a possible role for early antiretroviral therapy. AIDS Read. 14:41-49, 2004.
12. Lloyd, D., Turner, N.A., and Khunkitti, W. Encystation in Acanthamoeba castellanii: development of biocide resistance. J. Eukaryot. Microbiol. 48:11-16, 2001. (Pubitemid 32180364)
13. Khunkitti, W., Lloyd, D., Furr, J.R., et al. Aspects of the mechanisms of action of biguanides on trophozoites and cysts of Acanthamoeba castellanii. J. Appl. Microbiol. 82:107-114, 1997. (Pubitemid 27226957)
14. Hargrave, S.L., McCulley, J.P., and Husseini, Z. Results of a trial of combined propamidine isethionate and neomycin therapy for Acanthamoeba keratitis. Brolene Study Group. Ophthalmology 106:952-957, 1999. (Pubitemid 30191553)
15. Seal, D., Hay, J., Kirkness, C., et al. Successful medical therapy of Acanthamoeba keratitis with topical chlorhexidine and propamidine. Eye 10:413-421, 1996. (Pubitemid 26285546)
16. Kosrirukvongs, P., Wanachiwanawin, D., and Visvesvara, G.S. Treatment of Acanthamoeba keratitis with chlorhexidine. Ophthalmology 106:798-802, 1999.
17. Seijo Martinez, M., Gonzalez-Mediero, G., Santiago, P., et al. Granulomatous amebic encephalitis in a patient with AIDS: isolation of Acanthamoeba sp. group II from brain tissue and successful treatment with sulfadiazine and fluconazole. J. Clin. Microbiol. 38:3892-3895, 2000. (Pubitemid 30768483)
18. Singhal, T., Bajpai, A., Kalra, V., et al. Successful treatment of Acanthamoeba meningitis with combination oral antimicrobials. Pediatr. Infect. Dis. J. 20:623-627, 2001. (Pubitemid 32567727)
19. Kumar, R., and Lloyd, D. Recent advances in the treatment of Acanthamoeba keratitis. Clin. Infect. Dis. 35:434-441, 2002. (Pubitemid 34852574)
20. Mills, R. Microbial keratitis, what's the preferred initial therapy? View 1: corneal scraping and combination antibiotic therapy is indicated. Br. J. Ophthalmol. 87:1167-1169, 2003.
21. Schuster, F.L., and Visvesvara, G.S. Efficacy of novel antimicrobials against clinical isolates of opportunistic amebas. J. Eukaryot. Microbiol. 45:612-618, 1998.
22. Cervantes, F.L. Tratamiento médico de la amibiasis. Arch. Invest. Med. (Mex) 3:415-426, 1972.
23. Albach, R.A., and Booden, T. Parasitic Protozoa II. New York: Academic Press, 1978:455-485.
24. Knight, R. The chemotherapy of amoebiasis. J. Antimicrob. Chemother. 6:577-593, 1980.
25. Samarawickrema, N.A., Brown, D.M., Upcroft, J.A., et al. Involvement of superoxide dismutase and piruvate: ferredoxin oxidoreductase in mechanism of metronidazole resistance in Entamoeba histolytica. J. Antimicrob. Chemother. 40:833-840, 1997.
26. Wassman, C.A., Helberg, E., Tanich, E., et al. Metronidazole resistance in the protozoan parasite Entamoeba histolytica is associated with increased expression of iron containing superoxide dismutase and peroxiredoxin and decreased expression of ferredoxin- 1 and flavin reductase. J. Biol. Chem. 37:26051-26056, 1999. (Pubitemid 129520027)
27. Davis, P.H. Flora of Turkey and the East Aegean Islands, vol.7. Edinburgh: Edinburgh University Press, 1982.
28. Davis, P.H., Mill, R.R., and Tan, K. Flora of Turkey and the East Aegean Islands, vol.10. Edinburgh: Edinburgh University Press, 1988.
29. Guner, A., Ozhatay, N., Ekim, T., et al. Flora of Turkey and the East Aegean Islands. Vol.11., (Suppl-II). Edinburgh: Edinburgh University Press, 2000.
30. Chalchat, J.C., Michet, A., and Pasquier, B. Study of clones of Salvia officinalis L. yields and chemical composition of essential oil. Flav. Frag. J. 13:68-70, 1998. (Pubitemid 28130115)
31. Sokmen, A., Jones, B.M., and Erturk, M. The in vitro antibacterial activity of Turkish plants. J. Ethnopharmacol. 67:79-86, 1999.
32. Walochnik, J., Obwaller, A., and Aspock, H. Correlations between morphological, molecular biological, and physiological characteristics in clinical and nonclinical isolates of Acanthamoeba spp. Appl. Environ. Microbiol. 66:4408-4413, 2000. (Pubitemid 30768538)
33. Schuster, F.L. Cultivation of pathogenic and opportunistic freeliving amebas. Clin. Microbiol. 15:342-354, 2002.
34. International Standard ISO 7405. Preclinical evaluation of biocompatibility of medical devices used in dentistry-Test Methods for Dental Materials. Geneva: International Organization for Standardization, 1997.
35. Fiori, P.L., Mattana, A., Dessi, D., et al. In vitro acanthamoebicidal activity of a killer monoclonal antibody and a synthetic peptide. J. Antimicrob. Chemother. 57:891-898, 2006.
36. Radford, C.F., Lehmann, O.J., and Dart, J.K.G. Acanthamoeba keratitis: multicentre survey in England 1992-6. Br. J. Ophthalmol. 82:1387-1392, 1998.
37. Duguid, I.G., Dart, J.K., and Morlet, N. Outcome of Acanthamoeba keratitis treated with polyhexamethyl biguanide and propamidine. Ophthalmology 104:1587-1592, 1997. (Pubitemid 28053455)
38. Mattana, A., Biancu, G., and Alberti, L. In vitro evaluation of the effectiveness of the macrolide rokitamycin and chlorpromazine against Acanthamoeba castellanii. Antimicrob. Agents Chemother. 48:4520-4527, 2004. (Pubitemid 39577648)
39. Ficker, L., Seal, D., Warhurst, D., et al. Acanthamoeba keratitisresistance to medical therapy. Eye 4:835-838, 1990.
40. Ulubelen, A., Oksuz, S., Topcu, G., et al. Antibacterial diterpenes from the roots of Salvia blepharochlaena. J. Nat. Prod. 64:549-551, 2001. (Pubitemid 32423892)
41. Ulubelen, A., Topcu, G., Lotter, H., et al. Triterpenoids from the aerial parts of Salvia montbretii. Phytochemistry 36:413-416, 1994. (Pubitemid 2084408)
42. Topcu, G., and Ulubelen, A. Terpenoids from Salvia kronenburgii. J. Nat. Prod. 62:1605-1608, 1999.
43. Topcu, G., Altiner, E.A., Gozcu, S., et al. Studies on di- and triterpenoids from Salvia staminea with cytotoxic activity. Planta Med. 69:464-467, 2003. (Pubitemid 36774191)
44. Ulubelen, A., Birman, H., Oksuz, S., et al. Cardioactive Diterpenes from Salvia eriophora. Planta Med. 68:818-821, 2002.
45. Ulubelen, A. Cardioactive and antibacterial terpenoids from some Salvia species. Phytochemistry 64:395-399, 2003.
46. Zhou, L., Zuo, Z., and Chow, M.S.S. Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. Therapeutic reviews/herbal medicine. J. Clin. Pharmacol. 45:1345-1359, 2005. (Pubitemid 41643896)
47. Daniela, T. Salvia officinalis L. Part I. Botanic characteristics, composition, use and cultivation. Cesk. Farm. 42:111-116, 1993.
48. Velioglu, Y.S., Mazza, G., Gao, L., et al. Antioxidant activity and total phenolics in selected fruits, vegetables, and grain products. J. Agric. Food Chem. 46:4113-4117, 1998. (Pubitemid 128488501)